File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intracarotid abciximab injection to abort impending ischemic stroke during carotid angioplasty

TitleIntracarotid abciximab injection to abort impending ischemic stroke during carotid angioplasty
Authors
Issue Date2001
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/CED
Citation
Cerebrovascular Diseases, 2001, v. 11 n. 4, p. 300-304 How to Cite?
AbstractBackground: Abciximab, a platelet glycoprotein IIb/IIIa receptor antagonist, prevents ischemic complications during percutaneous transluminal coronary angioplasty and was recently shown to open occluded vessels in patients with acute myocardial infarction when used alone or in combination with other thrombolytic agents. In an animal model of arterial thrombosis, abciximab was found to be safe and effective for the prevention of carotid artery thrombosis. However, the safety and efficacy of abciximab in the treatment of acute ischemic cerebrovascular events is unknown at present. Case Description: We describe 3 patients who experienced ischemic cerebrovascular events with symptoms involving the middle cerebral artery territory while undergoing percutaneous angioplasty and stenting to their internal carotid arteries. Abciximab was administered to each patient within 10 min of symptom onset as a bolus (0.25 mg/kg) into the ipsilateral common carotid artery followed by continuous intravenous infusion (9 μg/min) for 12 h. All patients' symptoms resolved completely (by 25 min, 40 min and 5 h, respectively) with no further neurological complications. Conclusions: Our preliminary observation suggests that abciximab may improve neurological outcome following middle cerebral artery ischemic events associated with carotid angioplasty and stenting. Large prospective studies are warranted to establish the safety and efficacy of abciximab in acute ischemic stroke, either as a primary treatment modality or an adjunct to carotid angioplasty and stenting. Copyright © 2001 S. Karger AG, Basel.
Persistent Identifierhttp://hdl.handle.net/10722/76226
ISSN
2015 Impact Factor: 3.359
2015 SCImago Journal Rankings: 1.744
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHo, DSWen_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorChui, Men_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorHo, SLen_HK
dc.contributor.authorCheung, RTFen_HK
dc.date.accessioned2010-09-06T07:18:57Z-
dc.date.available2010-09-06T07:18:57Z-
dc.date.issued2001en_HK
dc.identifier.citationCerebrovascular Diseases, 2001, v. 11 n. 4, p. 300-304en_HK
dc.identifier.issn1015-9770en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76226-
dc.description.abstractBackground: Abciximab, a platelet glycoprotein IIb/IIIa receptor antagonist, prevents ischemic complications during percutaneous transluminal coronary angioplasty and was recently shown to open occluded vessels in patients with acute myocardial infarction when used alone or in combination with other thrombolytic agents. In an animal model of arterial thrombosis, abciximab was found to be safe and effective for the prevention of carotid artery thrombosis. However, the safety and efficacy of abciximab in the treatment of acute ischemic cerebrovascular events is unknown at present. Case Description: We describe 3 patients who experienced ischemic cerebrovascular events with symptoms involving the middle cerebral artery territory while undergoing percutaneous angioplasty and stenting to their internal carotid arteries. Abciximab was administered to each patient within 10 min of symptom onset as a bolus (0.25 mg/kg) into the ipsilateral common carotid artery followed by continuous intravenous infusion (9 μg/min) for 12 h. All patients' symptoms resolved completely (by 25 min, 40 min and 5 h, respectively) with no further neurological complications. Conclusions: Our preliminary observation suggests that abciximab may improve neurological outcome following middle cerebral artery ischemic events associated with carotid angioplasty and stenting. Large prospective studies are warranted to establish the safety and efficacy of abciximab in acute ischemic stroke, either as a primary treatment modality or an adjunct to carotid angioplasty and stenting. Copyright © 2001 S. Karger AG, Basel.en_HK
dc.languageengen_HK
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/CEDen_HK
dc.relation.ispartofCerebrovascular Diseasesen_HK
dc.rightsCerebrovascular Diseases. Copyright © S Karger AG.en_HK
dc.subject.meshAgeden_HK
dc.subject.meshAngioplastyen_HK
dc.subject.meshAntibodies, Monoclonal - administration & dosage - therapeutic useen_HK
dc.subject.meshBrain Ischemia - prevention & controlen_HK
dc.subject.meshCarotid Artery, Common - surgeryen_HK
dc.subject.meshCerebral Angiographyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunoglobulin Fab Fragments - administration & dosage - therapeutic useen_HK
dc.subject.meshInjections, Intra-Arterialen_HK
dc.subject.meshIntraoperative Complications - prevention & controlen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Cerebral Artery - pathologyen_HK
dc.subject.meshPlatelet Aggregation Inhibitors - administration & dosage - therapeutic useen_HK
dc.subject.meshStentsen_HK
dc.subject.meshStroke - prevention & controlen_HK
dc.subject.meshTomography, Emission-Computed, Single-Photonen_HK
dc.titleIntracarotid abciximab injection to abort impending ischemic stroke during carotid angioplastyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1015-9770&volume=11&spage=300&epage=304&date=2001&atitle=Intracarotid+Abciximab+injection+to+abort+impending+ischemic+stroke+during+carotid+angioplastyen_HK
dc.identifier.emailHo, SL:slho@hku.hken_HK
dc.identifier.emailCheung, RTF:rtcheung@hku.hken_HK
dc.identifier.authorityHo, SL=rp00240en_HK
dc.identifier.authorityCheung, RTF=rp00434en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000047657en_HK
dc.identifier.pmid11385208-
dc.identifier.scopuseid_2-s2.0-0034989263en_HK
dc.identifier.hkuros63458en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034989263&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume11en_HK
dc.identifier.issue4en_HK
dc.identifier.spage300en_HK
dc.identifier.epage304en_HK
dc.identifier.isiWOS:000169069200003-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridHo, DSW=7402970193en_HK
dc.identifier.scopusauthoridWang, Y=7601516613en_HK
dc.identifier.scopusauthoridChui, M=7003732062en_HK
dc.identifier.scopusauthoridWang, Y=36109095200en_HK
dc.identifier.scopusauthoridHo, SL=25959633500en_HK
dc.identifier.scopusauthoridCheung, RTF=7202397498en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats